HomeBUSINESS
BUSINESS

I/O in Lung Cancer - 3: Pfizer Sets Sights on Ovarian Cancer after NSCLC Trial Fails
(Aug.28.2018)

Dr Hirohashi (right), Ms Koreyuki in Interview with Jiho
By Takashi Ebisawa

After Bavencio (avelumab) failed in key PIII studies in lung and gastric cancer, how will Pfizer and Merck KGaA navigate their PD-L1 inhibitor through the fierce development race? Two Pfizer Japan oncology execs sat with Jiho to share their strategies ...
(LOG IN FOR FULL STORY)

News Calendar